Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

REPLIGEN CORPORATION

(RGEN)
  Report
Delayed Quote. Delayed Nasdaq - 12/08 04:00:00 pm
266.03 USD   +2.85%
11/22INSIDER SELL : Repligen
MT
11/17REPLIGEN CORPORATION : Technically solid
11/15INSIDER SELL : Repligen
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Repligen Corporation agreed to acquire Avitide, Inc. for approximately $280 million.

09/16/2021 EST

Repligen Corporation (NasdaqGS:RGEN) agreed to acquire Avitide, Inc. for approximately $280 million on September 16, 2021. $75 million in cash plus $75 million in Repligen common stock in addition to performance-based earnout payments over the next three years. To fund the transaction, Repligen intends to use its cash on hand, which totaled approximately $734 million at June 30, 2021. Avitide had revenues of $2.5 million in financial year 2020. The transaction is expected to be completed during the third quarter of 2021, subject to the satisfaction of customary closing conditions. The transaction is expected to be accretive to Repligen?s adjusted earnings per share in 2023. Perella Weinberg Partners (NasdaqGS:PWP) acted as financial advisor to Repligen Corporation. Goodwin Procter LLP acted as legal advisor to Repligen Corporation. Evan S. Yellin, David Zimbalist, Gerard Toohey, Ralph Bonavitacola and Matthew Nicastro of EC Mergers & Acquisitions acted as financial advisors to Avitide, Inc. Mark Stein and Mark Opitz of Morgan, Lewis & Bockius LLP acted as legal advisor to Avitide, Inc.


ę S&P Capital IQ 2021
All news about REPLIGEN CORPORATION
11/22INSIDER SELL : Repligen
MT
11/15INSIDER SELL : Repligen
MT
11/12Repligen Corporation to Present at Upcoming Investor Conferences
GL
11/08Repligen Releases Inaugural Sustainability Report
AQ
11/05Repligen Releases Inaugural Sustainability Report
AQ
11/04INSIDER SELL : Repligen
MT
11/02INSIDER SELL : Repligen
MT
10/29SVB Leerink Adjusts Price Target on Repligen to $325 from $260, Keeps Outperform Rating
MT
10/28REPLIGEN CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS ..
AQ
10/28Repligen Corporation Reports Earnings Results for the Third Quarter and Nine Months End..
CI
More news
Analyst Recommendations on REPLIGEN CORPORATION
More recommendations
Financials (USD)
Sales 2021 664 M - -
Net income 2021 128 M - -
Net cash 2021 431 M - -
P/E ratio 2021 115x
Yield 2021 -
Capitalization 14 301 M 14 301 M -
EV / Sales 2021 20,9x
EV / Sales 2022 17,4x
Nbr of Employees -
Free-Float 93,2%
Chart REPLIGEN CORPORATION
Duration : Period :
Repligen Corporation Technical Analysis Chart | RGEN | US7599161095 | MarketScreener
Technical analysis trends REPLIGEN CORPORATION
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 258,67 $
Average target price 318,11 $
Spread / Average Target 23,0%
EPS Revisions
Managers and Directors
Tony J. Hunt President, Chief Executive Officer & Director
Jon K. Snodgres Chief Financial Officer
Karen A. Dawes Chairman
Ralf Kuriyel Senior Vice President-Research & Development
James R. Bylund Senior Vice President-Global Operations & IT
Sector and Competitors
1st jan.Capi. (M$)
REPLIGEN CORPORATION29.20%14 301
ABBOTT LABORATORIES20.94%234 157
MEDTRONIC PLC-4.16%150 954
BECTON, DICKINSON AND COMPANY0.06%71 108
HOYA CORPORATION29.61%58 237
DEXCOM, INC.51.03%54 121